Catherine Thieblemont
University of Paris
215 Papers
814 Citations
Catherine Thieblemont is an academic researcher from University of Paris. The author has contributed to research in topics: Lymphoma & Medicine. The author has an hindex of 45, co-authored 215 publications. Previous affiliations of Catherine Thieblemont include University of Lyon & Paris-Sorbonne University.
Chat about Author
Papers
Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma.
Charles Dumontet,Franck Morschhauser,Philippe Solal-Celigny,Fadhela Bouafia,Emmanuelle Bourgeois,Catherine Thieblemont,Xavier Leleu,Olivier Hequet,Gilles Salles,B. Coiffier +9 more
TL;DR: Data suggest that gemcitabine displays activity in patients with MCL and CLL/lymphocytic lymphoma and severe non‐haematological toxicity was significant and should be taken into account in the design of future trials.
High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma.
Marie-Hélène Delfau-Larue,Marie-Hélène Delfau-Larue,Wolfram Klapper,Françoise Berger,Fabrice Jardin,Josette Brière,Gilles Salles,Olivier Casasnovas,Pierre Feugier,Corinne Haioun,Vincent Ribrag,Catherine Thieblemont,Michael Unterhalt,Martin Dreyling,Elizabeth Macintyre,Christiane Pott,Olivier Hermine,Eva Hoster +17 more
TL;DR: Despite immunochemotherapy, high-dose cytarabine, and ASCT, younger MCL patients with deletions of CDKN2A (p16) and TP53 show an unfavorable prognosis and are candidates for alternative therapeutic strategies.
ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma
Martin Dreyling,Catherine Thieblemont,Andrea Gallamini,Luca Arcaini,Elias Campo,Olivier Hermine,Johanna Kluin-Nelemans,Marco Ladetto,S. Le Gouill,E. Iannitto,S. A. Pileri,J. Rodriguez,Norbert Schmitz,Andrew Wotherspoon,Pier Luigi Zinzani,Emanuele Zucca +15 more
TL;DR: This consensus report focuses on the three less common lymphoproliferative malignancies: marginal zone lymphoma, mantle cell lymphomas, and peripheral T-cell lymphomas.
Frequency and significance of anemia in non-Hodgkin's lymphoma patients
I Moullet,Gilles Salles,Nicolas Ketterer,C. Dumontet,Fadela Bouafia,E.-M. Neidhart-Berard,Catherine Thieblemont,Pascale Felman,B. Coiffier +8 more
TL;DR: Anemia is an important adverse prognostic factor for the outcome of lymphoma patients, particularly in some histologic subgroups and in patients with bone marrow involvement.
Determinants of outcome in Covid-19 hospitalized patients with lymphoma: A retrospective multicentric cohort study.
Sylvain Lamure,Remy Dulery,Roberta Di Blasi,Adrien Chauchet,Cécile Laureana,Bénédicte Deau-Fischer,Bernard Drenou,Carole Soussain,Cédric Rossi,Nicolas Noel,Sylvain Choquet,Serge Bologna,Bertrand Joly,Milena Kohn,Sandra Malak,Guillemette Fouquet,Etienne Daguindau,Sophie Bernard,Catherine Thieblemont,Guillaume Cartron,Karine Lacombe,Caroline Besson +21 more
TL;DR: The characteristics of patients with lymphoma hospitalized for Coronavirus Disease 2019 (Covid-19) and the determinants of mortality were described and survival of patients younger than 70 years without relapsed/refractory lymphoma was comparable to that of the general population.